Fused bicyclic derivative, pharmaceutically acceptable salt, crystal form thereof and preparation method therefor
AssigneesJiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
InventorsTingting SHANG, Miaomiao ZHAO, Junran YANG, Zhenxing DU, Lin WANG, Qiyun SHAO, Jun FENG, Feng HE
Life of this patent
Estimating the term…
Abstract
Provided are a fused bicyclic derivative, a pharmaceutically acceptable salt, a crystal form thereof and a preparation method therefor. Specifically, provided are a hydrochloride, a mesylate, an acetate and a tartrate of the compound of formula (I), and a preparation method therefor and a crystal form thereof.
Claims22
A pharmaceutically acceptable salt of a compound of formula I, wherein the pharmaceutically acceptable salt is selected from hydrochloride, methanesulfonate, acetate, or tartrate,
A crystal form A of hydrochloride of a compound of formula I, which has an X-ray powder diffraction pattern comprising characteristic peaks at 2θ angles of 10.6, 11.4, 13.6, 17.6, 18.2, and 18.8, and the 2θ angle has an error range of ±0.2;
A crystal form A of methanesulfonate of a compound of formula I, which has an X-ray powder diffraction pattern comprising characteristic peaks at 2θ angles of 9.1, 11.0, 14.9, 16.2, and 17.0;
- or, a crystal form α of acetate of the compound of formula I, which has an X-ray powder diffraction pattern comprising characteristic peaks at 2θ angles of 8.9, 11.0, 14.9, 15.7, 17.0, and 19.7;
- or, a crystal form I of tartrate of the compound of formula I, which has an X-ray powder diffraction pattern comprising characteristic peaks at 2θ angles of 7.9, 8.6, 10.0, 10.9, 11.7, 13.9, 14.2, 14.4, 15.3, 16.4, 17.4, 17.8, 19.0, 20.1, 21.2, 21.5, 22.3, 23.7, 24.0, 24.6, 25.1, 26.3, 27.7, 28.7, 29.3, 30.6, and 30.9;
- the 2θ angle has an error range of ±0.2;
11-17. (canceled)
20-21. (canceled)
Dependencies are inferred from the claim text.